Ingrid Choong - 31 Aug 2023 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc.

Role
Chief Business Officer
Signature
/s/ James Vollins, Attorney-in-Fact for Ingrid C. Choong
Issuer symbol
N/A
Transactions as of
31 Aug 2023
Net transactions value
$0
Form type
4
Filing time
05 Sep 2023, 21:38:59 UTC
Previous filing
05 Sep 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EIGR Stock Option (Right to Buy) Award $0 +54,000 $0.000000 54,000 31 Aug 2023 Common Stock 54,000 $0.8640 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests in equal installments over 48 months measured from August 31, 2023, subject to the Reporting Person's continuous service as of each such date.